Intermediate-onset colorectal cancer: A clinical and familial boundary between both early and late-onset colorectal cancer.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2019
2019
Historique:
received:
17
02
2019
accepted:
23
04
2019
entrez:
17
5
2019
pubmed:
17
5
2019
medline:
14
1
2020
Statut:
epublish
Résumé
Comparative studies of colorectal cancer (CRC) according to the age of onset have found differences between early-onset CRC (EOCRC) and late-onset CRC (LOCRC). Using this as a starting point, we wished to determine whether intermediate-onset CRC (IOCRC) might also be considered as an independent group within CRC. We performed a retrospective comparative study of the clinicopathological and familial features, as well as of the symptoms and their duration, of a total of 272 subjects diagnosed with CRC classified into three groups according to the age-of-onset (98 EOCRC, 83 IOCRC and 91 LOCRC). The results show that from a clinicopathological point of view, IOCRC shared certain features with EOCRC (gender, prognosis), and with LOCRC (multiple primary CRCs), whereas it also had characteristics that were specific for IOCRC (mean number of associated polyps). A gradual progression was observed from EOCRC to LOCRC from a greater family aggregation to sporadic cases, in parallel with a change of Lynch Syndrome cases to the sporadic microsatellite instability pathway, with the IOCRC being a boundary group that is more related to EOCRC. With respect to symptoms, duration and correlation with stages, IOCRC appeared more similar to EOCRC. Clinically, IOCRC behaves as a transitional group between EOCRC and LOCRC, with features in common with both groups, but also with IOCRC-specific features. Excluding cases with familial cancer history, the awareness for EOCRC diagnosis should be extended to IOCRC.
Identifiants
pubmed: 31095598
doi: 10.1371/journal.pone.0216472
pii: PONE-D-19-04698
pmc: PMC6521992
doi:
Types de publication
Clinical Trial
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0216472Subventions
Organisme : NCI NIH HHS
ID : R01 CA202797
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA184792
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA187956
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA181572
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA072851
Pays : United States
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
PLoS One. 2013 Nov 21;8(11):e80015
pubmed: 24278232
Cancer Res. 1998 Aug 1;58(15):3455-60
pubmed: 9699680
Ann Surg Oncol. 2012 Sep;19(9):2814-21
pubmed: 22476818
Oncogene. 2002 May 9;21(20):3253-7
pubmed: 12082642
CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90
pubmed: 21296855
Int J Cancer. 2010 Dec 15;127(12):2893-917
pubmed: 21351269
Cancer Res. 1997 Mar 1;57(5):808-11
pubmed: 9041175
Clin Colorectal Cancer. 2017 Mar;16(1):31-37
pubmed: 27600984
Histopathology. 2013 Nov;63(5):603-15
pubmed: 23991632
Ann Surg Oncol. 2011 Nov;18(12):3285-91
pubmed: 21590452
Nat Rev Cancer. 2004 Dec;4(12):988-93
pubmed: 15573120
J Mol Diagn. 2014 Jan;16(1):116-26
pubmed: 24184227
Clin Transl Oncol. 2014 Dec;16(12):1072-8
pubmed: 25358801
Colorectal Dis. 2009 Jul;11(6):601-8
pubmed: 18637931
Mol Cancer. 2010 May 06;9:100
pubmed: 20459617
Clin Gastroenterol Hepatol. 2017 May;15(5):728-737.e3
pubmed: 27856366
Eur J Cancer. 2012 Mar;48(4):501-9
pubmed: 22226571
World J Gastroenterol. 2010 Aug 7;16(29):3697-703
pubmed: 20677343
PLoS One. 2012;7(9):e45357
pubmed: 23049789
PLoS One. 2014 Aug 01;9(8):e103159
pubmed: 25083765
Gastroenterology. 2004 Nov;127(5):1578-88
pubmed: 15521024
PLoS One. 2010 Nov 12;5(11):e13978
pubmed: 21103049
Mol Carcinog. 2016 May;55(5):705-16
pubmed: 25808986